While the recently announced collaboration between MIT and Pfizer is old news in terms of the product the two will be working on (namely, biologics), the focus of the collaboration—a simpler drug manufacturing methodology that cuts down steps in the purification process— if successful, has the potential to cut costs and help in the long run to bring down prices of biologics.

read more and comment